semaglutide polycystic kidney disease kidney disease - Ozempic forkidney diseasewithout diabetes semaglutide reduced kidney fat Semaglutide and Polycystic Kidney Disease: A Promising Frontier in Kidney Health

Nct06582875 Introduction

The landscape of kidney disease treatment is continually evolving, with a growing focus on understanding and intervening in the complex mechanisms that drive disease progression.Can GLP-1 receptor agonists slow the progression of ... Polycystic kidney disease (PKD), a genetic disorder characterized by the growth of numerous cysts in the kidneys, presents a significant health challenge, often leading to chronic kidney disease and ultimately kidney failure. In recent years, semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) primarily known for its role in managing type 2 diabetes and obesity, has emerged as a subject of intense research for its potential therapeutic benefits in various kidney conditions, including PKD and other forms of chronic kidney disease. This article delves into the emerging evidence surrounding semaglutide's impact on polycystic kidney disease, exploring its mechanisms of action, clinical trial findings, and the broader implications for kidney health.

Understanding Polycystic Kidney Disease (PKD)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, affecting approximately 1 in 500 to 1,000 individuals worldwide.作者：J Wu·2025·被引用次数：5—GLP-1RA Semaglutide Delays the Progression of ADPKDThrough Regulation of Glycolysis, Mitochondria Function and Ketosis. It is characterized by the development and growth of fluid-filled cysts from the nephrons in both kidneys. These cysts enlarge over time, compressing healthy kidney tissue, disrupting normal kidney function, and potentially leading to end-stage renal disease.Glucagon-Like Peptide-1 Receptor Agonist in ADPKD In addition to the kidneys, cysts can also form in other organs, such as the liver and pancreas2025年8月20日—The TGA has approvedsemaglutidefor reducing the risk ofkidneyfunction decline for adults with type 2 diabetes andchronic kidney disease. A .... The progression of ADPKD is influenced by various factors, including genetic mutations, age, and the presence of comorbidities like obesity and metabolic syndrome.

Semaglutide: A GLP-1 Receptor Agonist with Multifaceted Benefits

Semaglutide is a GLP-1 receptor agonist that mimics the action of the naturally occurring incretin hormone GLP-1. Its established benefits in diabetes management include improving glycemic control by increasing insulin secretion and reducing glucagon secretion, as well as promoting satiety and reducing appetite, which aids in weight loss. However, research has increasingly highlighted its cardiorenal protection properties, extending its therapeutic potential beyond metabolic controlClinical Trials.

Emerging Evidence: Semaglutide in Polycystic Kidney Disease

Recent research has begun to illuminate the promising role of semaglutide in slowing the progression of ADPKD.Treatment with Semaglutide normalizes mitochondrial ... Studies suggest that GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis. This groundbreaking insight indicates that semaglutide may exert its protective effects by influencing key cellular processes within the kidney.

Specifically, research indicates that treatment with Semaglutide decreases glucose uptake, ATP generation and glycolysis in Pkd1 mutant renal epithelial cells and tissues. The Pkd1 gene is crucial for kidney development and function, and mutations in this gene are a primary cause of ADPKD. By reducing glycolysis and cellular energy production, semaglutide may mitigate the metabolic derangements that contribute to cyst growth and kidney damageCan GLP-1 receptor agonists slow the progression of ....

Further investigations have demonstrated that semaglutide normalized mitochondrial fusion and morphology in Pkd1 mutant kidneys.Polycystic Kidney Disease | Can GLP-1 receptor agonists ... Mitochondria, the powerhouses of cells, play a critical role in cellular energy production and overall kidney health. Dysfunctional mitochondria are implicated in the pathogenesis of various kidney diseases, and semaglutide's ability to restore their normal function is a significant finding.Study results show promising effects of semaglutide for ...

Beyond these cellular mechanisms, clinical trials are exploring the efficacy of semaglutide in slowing growth and progression in individuals with polycystic kidney disease. A notable clinical trial aims to determine if semaglutide can slow kidney growth in patients with polycystic kidney disease who are overweight. This aligns with the understanding that obesity can accelerate kidney disease progression in ADPKD.

Semaglutide's Broader Impact on Chronic Kidney Disease

The benefits of semaglutide are not exclusive to ADPKD.Treatment withSemaglutidenormalizes mitochondrial fusionandmorphology in Pkd1 mutantkidneys. (AandB) Relative mRNA levels of mitochondrial oxidative ... Studies have shown its effectiveness in managing other forms of chronic kidney disease (CKD), particularly in patients with type 2 diabetes.Reduction inKidneyDamage Markers: Compared to the placebo group, participants receivingsemaglutideshowed a 52% reduction in UACR. This suggests lesskidney... The FLOW trial results indicated that semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.Can GLP-1 receptor agonists slow the progression ... - Springer This significant finding has led to regulatory approvals in several regions. For instance, Ozempic (semaglutide, Novo Nordisk) is now approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease. Furthermore, regulatory bodies have approved injectable forms of semaglutide to treat chronic kidney disease in individuals with type 2 diabetes. Preliminary evidence from studies suggests that semaglutide may help fight chronic kidney disease by reducing kidney fat and improving glomerular hemodynamics.

Clinical Trial Findings and Future Directions

Several clinical trials are actively investigating the effects of semaglutide on kidney healthNCT04865770 | A Research Study to Find Out How .... One study reported that semaglutide was associated with a 24% reduction in major kidney disease events and a slower annual eGFR decline by 1.Obesity and metabolic syndrome are known to accelerate kidney disease progression inADPKD. Observations from the TEMPO 3:4 trial demonstrated that overweight ...16 mL/min. Compared to placebo, participants receiving semaglutide showed a 52% reduction in UACR (urine albumin-to-creatinine ratio), a key marker of kidney damage.

Research is also exploring the potential of semaglutide in improving kidney transplant eligibility. In a study, nearly half of patients with end-stage kidney disease who were initially ineligible for kidney transplant achieved waitlist activation after one year of semaglutide treatment.

The scientific community is actively pursuing further research, including studies exploring the efficacy of semaglutide and lisinopril as therapeutic agents for chronic kidney disease, and investigating the effectiveness of semaglutide once weekly as an add-on therapy for T2DM-CKD (type 2 diabetes mellitus and chronic kidney disease).

Important Considerations and Safety Information

While the evidence for semaglutide's benefits in kidney disease is compelling, it is crucial to acknowledge that it is a prescription medication with specific usage guidelines and potential side effects. Important Safety Information | Ozempic® (semaglutide) injection 0.5 mg or ... should always be reviewedI tried therapy and it helped a little, butsemaglutideshuts off the physiological problem. I was diagnosed withPKDat age 38. I yo-yo dieted .... It is essential for patients to consult with their healthcare providers to determine if semaglutide is an appropriate treatment option for their specific condition, including polycystic kidney disease or other forms of chronic kidney disease. Healthcare professionals play a vital role in monitoring patient response and managing any adverse events. It is important to note that certain hereditary kidney diseases, including polycystic kidney disease, can be exclusion criteria for some research studies, underscoring the complexity of investigating drug effects in diverse patient populationsWe are doing this study to learn more about howsemaglutide may help fight chronic kidney diseasein people with type 2 diabetes..

Conclusion

The emerging research on semaglutide and polycystic kidney disease represents a significant step forward in the management of this challenging condition6 things to know about GLP1-RAs and CKD. By influencing fundamental cellular processes such as glycolysis, mitochondria function, and ketosis, and by demonstrating profound benefits in slowing the progression of chronic kidney disease, semaglutide offers a new avenue of hope for patients at risk of or living with kidney disease. As research continues and more clinical data becomes available, semaglutide may emerge as a cornerstone therapy for protecting kidney health and improving outcomes for individuals affected by PKD and other renal ailments. The ongoing exploration of GLP-1 receptor agonists in ADPKD signifies a promising future for innovative treatments in nephrology.GLP-1 Receptor Agonists (GLP-1 RAs)